SCHEMBL12827243

SCHEMBL12827243

Cc1cc([C@@H](C)NC(=O)C2CC2c2ccc(C(F)(F)F)cc2)ccc1C(=O)OSN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.47
FFAR1 O14842 3/20 0.45
CHRNA7 P36544 3/20 0.41
PTGER4 P35408 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CNR1 P21554 1/20 0.35
PRCP P42785 2/20 0.35
ROCK2 O75116 2/20 0.35
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12827546 0.92 CHRNA7 (0.41) KCNH2FFAR1CHRNA7ALDH1A1POLB
SCHEMBL12827547 0.89 KCNH2 (0.45) KCNH2FFAR1CHRNA7PTGER4CNR1
SCHEMBL12827772 0.84 CHRNA7 (0.37) KCNH2FFAR1CHRNA7ALDH1A1CYP1A2
SCHEMBL12827544 0.84 CHRNA7 (0.41) KCNH2FFAR1CHRNA7POLBTDP1
SCHEMBL12827242 0.83 CHRNA7 (0.39) KCNH2FFAR1CHRNA7POLBTDP1
SCHEMBL12827095 0.80 PTGER4 (0.38) KCNH2PTGER4
SCHEMBL12827343 0.79 PTGER4 (0.36) KCNH2PTGER4ALDH1A1KDM4EPOLB
SCHEMBL12827781 0.78 PTGER4 (0.38) KCNH2PTGER4ALDH1A1CYP1A2CYP3A4
SCHEMBL5814892 0.78 KCNH2 (0.48) KCNH2FFAR1CHRNA7CNR1
SCHEMBL1473592 0.78 KCNH2 (0.48) KCNH2FFAR1CHRNA7CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 KCNH2 43/4885FFAR1 21/4885CHRNA7 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.